Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether four new alternative imaging methods can be used to follow the response of breast cancer to the treatment patients are being given. These methods produce an image of the inside of the breast so that doctors can better decide whether breast cancer is responding to therapy. An important part of the study is to examine the same person with all methods in order to directly compare results. The four methods are: MRI Elasticity Imaging (abbreviated MRE), Electrical Impedance Spectroscopy (abbreviated EIS), Microwave Imaging and Spectroscopy (abbreviated MIS), Near Infrared Spectroscopy (abbreviated NIR). In addition to the experimental imaging methods, patients may also undergo a contrast-enhanced MRI, and/or additional mammography, which will help researchers compare the experimental methods. These additional examinations are accepted diagnostic procedures; they are not experimental. Some participants will have one or both of these additional examinations if clinically indicated.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01837563
Study type	Observational
Source	Dartmouth-Hitchcock Medical Center
Contact
Status	Terminated
Phase	N/A
Start date	September 2006
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01048918` - Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT05744375` - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Phase 2
Recruiting	`NCT03978663` - Three Fraction Radiation to Induce Immuno-Oncologic Response	N/A
Active, not recruiting	`NCT04352777` - Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer	Phase 2
Recruiting	`NCT06064812` - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.	Phase 1
Recruiting	`NCT05963997` - A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT06080620` - The Choice of Treatment Methods and Efficacy of LABC	N/A
Active, not recruiting	`NCT05002868` - Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors	Phase 1
Active, not recruiting	`NCT02595762` - A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Active, not recruiting	`NCT02965950` - The p53 Breast Cancer Trial	Phase 2
Completed	`NCT01785992` - A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.	Phase 2
Completed	`NCT00764036` - Study of Artesunate in Metastatic Breast Cancer	Phase 1
Active, not recruiting	`NCT03685331` - HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer	Phase 1
Completed	`NCT05021900` - Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer	Phase 2
Withdrawn	`NCT04088032` - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer	Early Phase 1
Completed	`NCT00455273` - Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
Terminated	`NCT04042051` - Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Phase 1
Recruiting	`NCT05582499` - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	Phase 1/Phase 2
Recruiting	`NCT05749016` - Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer	Phase 2